Continuous Glucose Monitoring (CGM) Devices Market to Reach USD 10.72 Billion by 2033 | North America Holds 43.7% Market Share | Key Players: Abbott, Dexcom, Medtronic plc

The global Continuous Glucose Monitoring (CGM) Devices market was valued at USD 6.06 billion in 2025 and is projected to reach USD 10.72 billion by 2033, growing at a CAGR of 8.1% during the forecast period from 2026 to 2033. The market presents a strong growth opportunity driven by the rising global prevalence of diabetes, increasing adoption of wearable healthcare technologies, and growing emphasis on continuous, real-time glucose monitoring for improved disease management. Continuous glucose monitoring devices enable patients and healthcare providers to track glucose levels throughout the day without frequent finger-stick testing, improving glycemic control, reducing the risk of hypoglycemia, and supporting personalized diabetes care. Growing awareness of preventive healthcare, favorable reimbursement policies, and increasing adoption of connected diabetes management solutions are further accelerating market growth.

The market is further benefiting from rapid advancements in sensor technology, artificial intelligence, mobile health applications, and cloud-based data analytics that enhance monitoring accuracy, patient engagement, and clinical decision-making. Leading medical device manufacturers are focusing on developing smaller, longer-lasting, factory-calibrated sensors with improved comfort and seamless integration with insulin pumps, smartphones, and automated insulin delivery systems. Recent industry developments include the expansion of over-the-counter CGM products, regulatory approvals for next-generation wearable glucose sensors, broader integration of AI-powered predictive analytics, and strategic collaborations between diabetes technology companies and digital health providers to strengthen connected care ecosystems. In addition, increasing adoption of CGM devices among individuals with Type 2 diabetes, gestational diabetes, and high-risk populations is creating significant opportunities for market expansion. As healthcare systems continue to prioritize remote patient monitoring, personalized medicine, and digital chronic disease management, the continuous glucose monitoring devices market is expected to offer substantial long-term growth potential and an attractive business landscape for device manufacturers, healthcare providers, and investors worldwide.

Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID):https://www.datamintelligence.com/download-sample/continuous-glucose-monitoring-devices-market?sai-v

Key Developments
July 2026: The United States strengthened diabetes management innovation as Dexcom, Inc. expanded its next-generation continuous glucose monitoring (CGM) platform with enhanced AI-powered glucose insights and broader integration with digital health and insulin delivery systems.

June 2026: United States-based Abbott Laboratories expanded the availability of its FreeStyle Libre CGM portfolio across additional international markets, improving access to real-time glucose monitoring for people with diabetes.

May 2026: Europe accelerated the adoption of connected diabetes care as Medtronic plc enhanced interoperability between its CGM systems and automated insulin delivery (AID) platforms, supporting personalized diabetes management.

April 2026: Japan strengthened digital diabetes care initiatives as Terumo Corporation expanded collaborations to advance wearable glucose monitoring technologies and remote patient management solutions.

March 2026: China increased investments in locally developed CGM technologies as Sinocare Inc. expanded production capacity and introduced advanced continuous glucose monitoring solutions to meet the growing demand for diabetes management devices.

February 2026: North America witnessed growing partnerships among healthcare providers, digital health companies, and CGM manufacturers to improve remote patient monitoring, data-driven diabetes management, and access to reimbursement.

January 2026: The Asia-Pacific region experienced growing adoption of wearable CGM devices as governments and healthcare providers expanded digital health initiatives to improve diabetes screening, continuous monitoring, and long-term disease management.

Key Players
Abbott | Dexcom, Inc. | Medtronic plc | Ascensia Diabetes Care Holdings AG | F. Hoffmann-La Roche Ltd. | iHealth Labs Inc. | Ypsomed AG | Medtrum Technologies Inc. | Menarini Diagnostics S.r.l. | Nemaura Medical Inc. | Senseonics Holdings, Inc. | Glucovation, Inc. | Afon Technology | Signos Inc. | Others

Key Highlights
Abbott - Holds a 29.6% share, driven by its FreeStyle Libre continuous glucose monitoring platform, broad global distribution network, strong reimbursement coverage, and continuous product innovation.

Dexcom, Inc. - Holds a 26.4% share, supported by its high-accuracy CGM systems, real-time glucose monitoring capabilities, strong healthcare provider adoption, and expanding global presence.

Medtronic plc - Holds a 14.2% share, strengthened by its integrated insulin pump and CGM ecosystem, advanced diabetes management solutions, and extensive clinical expertise.

Ascensia Diabetes Care Holdings AG - Holds a 6.1% share, fueled by its diabetes management portfolio, strategic partnerships in CGM technologies, and expanding digital health capabilities.

F. Hoffmann-La Roche Ltd. - Holds a 4.9% share, supported by its diabetes care solutions, connected glucose monitoring technologies, and strong presence in diagnostic healthcare.

iHealth Labs Inc. - Holds a 3.8% share, driven by its connected health devices, mobile-enabled glucose monitoring solutions, and growing consumer healthcare ecosystem.

Ypsomed AG - Holds a 3.4% share, strengthened by its insulin delivery systems, digital diabetes management solutions, and strategic collaborations in CGM integration.

Medtrum Technologies Inc. - Holds a 2.7% share, supported by its wireless CGM systems, patch pump technologies, and expanding footprint in diabetes care markets.

Menarini Diagnostics S.r.l. - Holds a 2.1% share, fueled by its diagnostic expertise, diabetes monitoring portfolio, and growing presence in European healthcare markets.

Nemaura Medical Inc. - Holds a 1.9% share, driven by its non-invasive glucose monitoring technologies and innovative wearable diabetes management solutions.

Senseonics Holdings, Inc. - Holds a 1.7% share, supported by its long-term implantable CGM systems, advanced sensor technology, and differentiated diabetes care platform.

Glucovation, Inc. - Holds a 1.1% share, strengthened by its next-generation glucose sensing technologies and focus on continuous metabolic monitoring innovation.

Afon Technology - Holds a 0.9% share, supported by its non-invasive glucose monitoring research, optical sensing technologies, and product development initiatives.

Signos Inc. - Holds a 0.7% share, driven by its AI-enabled metabolic health platform, CGM-based health insights, and personalized wellness solutions.

Others - Hold a combined 0.5% share, comprising emerging CGM manufacturers, wearable health technology companies, and innovative diabetes management solution providers.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=continuous-glucose-monitoring-devices-market?sai-v

Market Drivers
Increasing prevalence of diabetes, rising awareness of continuous glucose monitoring, and growing demand for effective diabetes management solutions are significantly driving growth of the Continuous Glucose Monitoring (CGM) Devices market worldwide.

Rising adoption of real-time glucose monitoring technologies among patients with Type 1 and Type 2 diabetes is accelerating market expansion by enabling better glycemic control and reducing the risk of diabetes-related complications.

Growing preference for minimally invasive and wearable glucose monitoring devices over traditional fingerstick blood glucose testing is strengthening demand for advanced CGM systems.

Increasing integration of CGM devices with insulin pumps, smart insulin pens, mobile applications, and digital diabetes management platforms is improving patient convenience and treatment outcomes.

Advancements in sensor technology, wireless connectivity, artificial intelligence, predictive analytics, and extended sensor wear duration are enhancing device accuracy, usability, and patient adherence.

Expansion of telehealth services, remote patient monitoring programs, and digital healthcare ecosystems is increasing the adoption of CGM devices for continuous diabetes care.

Growing investments by medical device manufacturers, healthcare providers, and governments in diabetes management technologies and reimbursement programs are supporting market growth.

Rising focus on personalized diabetes care, preventive healthcare, and early intervention strategies is further propelling the global Continuous Glucose Monitoring (CGM) Devices market.

Industry Developments
Rapid advancement in next-generation CGM sensors, factory-calibrated devices, AI-powered glucose analytics, and extended-wear technologies improving monitoring accuracy and patient experience.

Increasing adoption of integrated diabetes management solutions combining CGM devices with insulin delivery systems, mobile health applications, and cloud-based data platforms supporting personalized treatment.

Growing investments in non-invasive glucose monitoring research, wearable biosensors, and digital health technologies accelerating innovation across the CGM ecosystem.

Expansion of collaborations among medical device manufacturers, healthcare providers, pharmaceutical companies, and digital health organizations driving development of comprehensive diabetes management solutions.

Rising integration of artificial intelligence, remote patient monitoring, and predictive glucose management technologies enhancing clinical decision-making and patient engagement.

Strategic product launches, regulatory approvals, acquisitions, and geographic expansion initiatives by leading CGM manufacturers supporting global market growth and broader accessibility.

Continuous improvements in sensor accuracy, device miniaturization, wireless connectivity, interoperability, and battery life enhancing reliability, comfort, and long-term diabetes management.

Regional Insights
North America 43.7% share: Leads the market due to high diabetes prevalence, advanced healthcare infrastructure, favorable reimbursement policies, strong adoption of wearable medical technologies, and the presence of leading CGM device manufacturers.

Europe 27.6% share: Strong market presence driven by increasing awareness of diabetes management, supportive healthcare reimbursement systems, growing adoption of digital health technologies, and expanding access to continuous glucose monitoring devices.

Asia Pacific 22.4% share: Fastest-growing region supported by rising diabetes incidence, expanding healthcare infrastructure, increasing healthcare expenditure, and growing adoption of advanced diabetes monitoring technologies across China, Japan, India, and South Korea.

Latin America 3.8% share: Growth supported by improving diabetes awareness, expanding access to healthcare services, and increasing adoption of wearable glucose monitoring devices, particularly in Brazil and Mexico.

Middle East & Africa 2.5% share: Emerging growth driven by rising diabetes burden, improving healthcare infrastructure, increasing government initiatives for chronic disease management, and growing availability of advanced glucose monitoring solutions.

Key Segments
➥ By Component

Sensors: Represents the dominant segment, driven by recurring replacement demand, continuous glucose measurement requirements, and advancements in sensor accuracy and wear duration.

Transmitters: Represents a significant segment, supported by increasing adoption of wireless data transmission technologies for real-time glucose monitoring.

Receivers: Represents a substantial segment, fueled by growing demand for dedicated monitoring devices and seamless integration with smartphones and insulin management systems.

➥ By Connectivity

Bluetooth: Represents the dominant segment, driven by widespread integration with smartphones, wearable devices, and mobile health applications for real-time glucose tracking.

Wi-Fi: Represents a growing segment, supported by increasing demand for cloud connectivity, remote patient monitoring, and continuous data sharing with healthcare providers.

➥ By Application

Type 1 Diabetes: Represents the dominant segment, driven by the need for continuous glucose monitoring, intensive insulin therapy, and effective glycemic control.

Type 2 Diabetes: Represents a significant and rapidly growing segment, supported by the rising global prevalence of diabetes and increasing adoption of CGM devices for disease management.

Gestational Diabetes: Represents a growing segment, fueled by increasing awareness of maternal health and the need for continuous glucose monitoring during pregnancy.

Prediabetes: Represents a moderate segment, driven by growing emphasis on early detection, preventive healthcare, and lifestyle management.

➥ By End-User

Hospitals & Clinics: Represents the dominant segment, driven by widespread use of CGM devices for inpatient diabetes management, diagnosis, and treatment optimization.

Homecare Settings: Represents a rapidly growing segment, supported by increasing patient preference for remote monitoring, self-management, and improved convenience.

Diagnostic Centers: Represents a significant segment, fueled by growing utilization of CGM systems for diabetes screening, assessment, and disease monitoring.

Others: Represents a moderate segment, supported by adoption across ambulatory care centers, research institutions, and specialty diabetes clinics.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/continuous-glucose-monitoring-devices-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.